id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-E-0182-0008,FDA,FDA-2014-E-0182,Notice of Final Determination Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2016-12-28T05:00:00Z,2016,12,2016-12-28T05:00:00Z,,2016-12-28T14:43:08Z,,0,0,090000648243a977
FDA-2014-E-0182-0007,FDA,FDA-2014-E-0182,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2016-08-01T04:00:00Z,2016,8,2016-08-01T04:00:00Z,,2016-08-02T02:34:05Z,,0,0,090000648214b318
FDA-2014-E-0182-0006,FDA,FDA-2014-E-0182,"Determination of Regulatory Review Period for Purposes of Patent
Extension; VIZAMYL",Notice,Determinations,2015-12-15T05:00:00Z,2015,12,2015-12-15T05:00:00Z,2016-02-17T04:59:59Z,2015-12-15T15:50:05Z,2015-31401,0,0,0900006481da740f
FDA-2014-E-0182-0005,FDA,FDA-2014-E-0182,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-11-12T05:00:00Z,2015,11,2015-11-12T05:00:00Z,,2015-11-12T18:51:54Z,,0,0,0900006481d3a5d3
FDA-2014-E-0182-0004,FDA,FDA-2014-E-0182,Letter from the U.S. Patent and Trademark Office to FDA,Other,Letter(s),2015-03-25T04:00:00Z,2015,3,2015-03-25T04:00:00Z,,2015-03-25T16:56:52Z,,0,0,0900006481a6424d
FDA-2014-E-0182-0003,FDA,FDA-2014-E-0182,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2014-03-27T04:00:00Z,2014,3,2014-03-27T04:00:00Z,,2014-03-27T16:31:44Z,,0,0,0900006481686bb9
FDA-2014-E-0182-0002,FDA,FDA-2014-E-0182,Patent Extension from Arnold & Porter LLP (on behalf of GE Healthcare Limited),Other,Application,2014-02-06T05:00:00Z,2014,2,2014-02-06T05:00:00Z,,2014-02-06T15:52:01Z,,0,0,090000648154cc67
FDA-2014-E-0182-0001,FDA,FDA-2014-E-0182,U.S. Patent and Trademark Office,Other,Letter(s),2014-02-06T05:00:00Z,2014,2,2014-02-06T05:00:00Z,,2014-02-06T15:50:56Z,,0,0,090000648154cccb